Biopharma Co. Blasts 'Excessive' Fee Bid In Board Pay Case

By Rose Krebs (September 22, 2022, 4:31 PM EDT) -- After striking a tentative deal to settle a Delaware Chancery suit he filed over alleged "grossly excessive" director pay, an investor plaintiff is now seeking an "excessive" payday for his attorneys, Sage Therapeutics Inc. has told the court....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!